The biotech company’s pivot into digital assets marks one of the largest treasury financings to date, underscoring growing institutional demand for tokenized finance.
The biotech company’s pivot into digital assets marks one of the largest treasury financings to date, underscoring growing institutional demand for tokenized finance.
